• Journal of Pharmaceutical Investigation
• /
• v.37 no.3
• /
• pp.197-203
• /
• 2007

A bioequivalence study of $Dilast^{TM}$ Capsule (Chong Kun Dang Pharma. Co., Ltd.) to $Ketas^{(R)}$ Capsule (Han Dok Pharma. Co., Ltd.) was conducted according to the guidelines of Korea Food and Drug Administration (KFDA). Twenty eight healthy male Korean volunteers received each medicine at the ibudilast dose of 20 mg in a $2{\times}2$ crossover study. There was one week wash-out period between the doses. Plasma concentrations of ibudilast were monitored by a liquid chromatography-tandem mass spectrometry (LC-MS/MS) for over a period of 36 hours after drug administration. $AUC_t$ (the area under the plasma concentration-time curve from time zero to 36 hr) was calculated by the linear trapezoidal rule method. $C_{max}$ (maximum plasma drug concentration) and $T_{max}$ (time to reach $C_{max}$) were compiled from the plasma concentration-time data. Analysis of variance was carried out using logarithmically transformed $AUC_t\;and\;C_{max}$. No significant sequence effect was found for all of the bioavailability parameters indicating that the crossover design was properly performed. The 90% confidence intervals of the $AUC_t$ ratio and the $C_{max}$ ratio for $Dilast^{TM}$ $Capsule/Ketas^{(R)}$ Capsule were $log0.93{\sim}log1.06$ and $log0.93{\sim}log1.11$, respectively. These values were within the acceptable bioequivalence intervals of $log0.80{\sim}log1.25$. Thus, our study demonstrated the bioequivalence of $Dilast^{TM}$ Capsule and $Ketas^{(R)}$ Capsule with respect to the rate and extent of absorption.

• Journal of Pharmaceutical Investigation
• /
• v.37 no.4
• /
• pp.255-261
• /
• 2007

A bioequivalence study of $Nimegen^{TM}$ soft capsule (Medica Korea Pharma. Co., Ltd.) to $RoAccutane^{(R)}$ soft capsule (Roche Korea Ind. Co., Ltd.) was conducted according to the guidelines of Korea Food and Drug Administration (KFDA). Thirty healthy male Korean volunteers received each medicine at the isotretinoin dose of 60 mg in a $2{\times}2$ crossover study. There was one week wash-out period between the doses. Plasma concentrations of isotretinoin were monitored by a high performance liquid chromatography (HPLC) for over a period of 48 hours after drug administration. $AUC_t$ (the area under the plasma concentration-time curve from time zero to 48 hr) was calculated by the linear trapezoidal rule method. $C_{MAX}$ (maximum plasma drug concentration) and $T_{MAX}$ (time to reach $C_{MAX}$) were compiled from the plasma concentration-time data. Analysis of variance was carried out using logarithmically transformed $AUC_t\;and\;C_{MAX}$. No significant sequence effect was found for all of the bioavailability parameters indicating that the crossover design was properly performed. The 90% confidence intervals of the $AUC_t$ ratio and the $C_{MAX}$ ratio for $Nimegen^{TM}/RoAccutane^{(R)}$ were $log0.860{\sim}log0.98\;and\;log0.85{\sim}log1.00$, respectively. These values were within the acceptable bioequivalence intervals of $log0.80{\sim}log1.25$. Thus, our study demonstrated the bioequivalence of $Nimegen^{TM}\;and\;RoAccutane^{(R)}$ with respect to the rate and extent of absorption.

• Journal of environmental and Sanitary engineering
• /
• v.3 no.2 s.5
• /
• pp.99-106
• /
• 1988

In order to analyze trace metals by Atomic absorption spectrophotometer in infant formula milk powder, Wet digestion method using nitric acid, perchloric acid mainly and D.D.T.C.-M.I.B.K. extraction method were done. The r-value of calibration curve were more than 0.999 in Cu, Mn, Zn. Recovery test showed high recovery rate of $97-104\%$. The results were as follows: Averages of total samples were Cu $1.92\pm1.24 ppm,\;Mn\;1.18\pm1.01ppm,\;Zn\;22.43\pm8.88ppm.$ Averages of Common Infant formula were Cu1.96\pm1.26ppm,\;Mn\;1.0\pm0.57ppm,\;Zn\;21.52\pm9.72ppm.$ Averages of follow-up infant formula were Cu$1.89\pm1.26ppm,\;Mn\;1.36\pm1.31ppm,\;Zn\;23.34\pm8.7 ppm$.

• Proceedings of the KIEE Conference
• /
• 1992.07b
• /
• pp.1041-1044
• /
• 1992

A solar cell should be operated at the maximum output point on the I-V characteristic curve with constant current and constant voltage in order that the solar energy be fully utilized. According to, in this paper, we describes a controller which can track the maximum power point of a solar arry using current and voltage ripple variation of step up chopper system. The control circuit is desinged such that actual current and voltage are sensed directly from the solar cell array. These two signal are then holded sampling and multiplies by a single chip multiplier.

• Journal of the Korean Mathematical Society
• /
• v.36 no.1
• /
• pp.193-207
• /
• 1999

Let ${\gamma}$ : Ilongrightarrow R2 be a sufficiently smooth curve and $\sigma$${\gamma}$ be the affine arclength measure supported on ${\gamma}$. In this paper, we study the Lp - improving properties of the convolution operators T$\sigma$${\gamma}$ associated with $\sigma$${\gamma}$ for various curves ${\gamma}$. Optimal results are obtained for all finite type plane curves and homogeneous curves (possibly blowing up at the origin). As an attempt to extend this result to infinitely flat curves we give and example of a family of flat curves whose affine arclength measure has same Lp-improvement property. All of these results will be based on uniform estimates of damping oscillatory integrals.

• Honam Mathematical Journal
• /
• v.36 no.2
• /
• pp.233-251
• /
• 2014

In this paper, position vector of a spacelike slant helix with respect to standard frame are deduced in Minkowski space $E^3_1$. Some new characterizations of a spacelike slant helices are presented. Also, a vector differential equation of third order is constructed to determine position vector of an arbitrary spacelike curve. In terms of solution, we determine the parametric representation of the spacelike slant helices from the intrinsic equations. Thereafter, we apply this method to find the parametric representation of some special spacelike slant helices such as: Salkowski and anti-Salkowski curves.

• 한국초전도학회:학술대회논문집
• /
• v.12
• /
• pp.20-20
• /
• 2002

• Proceedings of the Korean Society for Technology of Plasticity Conference
• /
• 2009.05a
• /
• pp.129-134
• /
• 2009

The dimension of forged part is different from that of die. Therefore, a more precise die dimension is necessarys to produce the precise part, considering the dimensional changes from forging die to final part. In this paper, both experimental and FEM analysis are performed to investigate the effect of several features including die dimension at each forging step and heat-treatment on final part accuracy in the closed-die upsetting. The dimension of forged part is checked at each stage as machined die, cold forged, and post-heat-treatment steps. The elastic characteristics and thermal influences on forging stage are analyzed numerically by the DEFORM-$2D^{TM}$. The effect of residual stress after heat-treatment on forged part could be considered successfully by using DEFOAM-$HT^{TM}$.

• Proceedings of the Korean Institute of Electrical and Electronic Material Engineers Conference
• /
• 2009.06a
• /
• pp.293-294
• /
• 2009

We proposed a novel single gap transflective liquid crystal display (LCD) using liquid crystal with negative dielectric anisotropy. We designed cell structure driven by fringe electric field in the transmissive (T) part and vertical electric field in the reflective (R) part. In the device, high surface pretilt angle of the LC in the R-part is achieved through polymerization of an UV curable reactive mesogen (RM) monomer at surfaces. By optimizing the parameters, a newly developed transflective display has characteristics such as single gap and single gamma curve.

• Proceedings of the Korean Society of Applied Pharmacology
• /
• 1997.04a
• /
• pp.117-117
• /
• 1997

Sandimmune Neoral$\^$(R)/ and Neoplanta$\^$(R)/ capsules were administered to twenty four healthy Korean male subjects at a cyclosporin A (CsA) dose of 175 mg in a 2 ${\times}$ 2 crossover investigation with a two-week wash-out phase. Concentrations of CsA in blood were measured by RIA method for over a period of 48 h. Result : The two formulations were found bioequivalent, but analysis of variance (ANOVA) indicated that there is a significant (p<0.01) period effect in AUC$\_$0-LAST/ (area under the blood concentration above assay limit of quantification-time curve) and C$\_$MAX/ (maximum blood concentration) between the administrations. Paired t-test revealed 6 and 9% decreases in AUC$\_$0-LAST/ and C$\_$MAX/, respectively at the second administration. This period effect on the pharmacokinetics of CsA may be relevant for the patients who need consecutive administration of the drug. A number of mechanisms, such as induction of the enzymes responsible for metabolism of the drug in the gut wall and/or liver and modulation of P-glycoprotein upon the consecutive dosing, appear consistent with the change, and needs experimental proof.